HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

NCT06112704 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: HS-20093

Sponsor

Hansoh BioMedical R&D Company